Ab­b­Vie’s Rin­voq pass­es PhI­II AD test; Dicer­na races Al­ny­lam; New Sarep­ta gene & cell col­lab

→ Al­most a year af­ter it was ap­proved for rheuma­toid arthri­tis, Ab­b­Vie’s JAK in­hibitor Rin­voq was shown for the first time to work as a monother­a­py in atopic der­mati­tis. In a Phase III study, two dif­fer­ent dos­es of the drug beat place­bo on all pri­ma­ry and sec­ondary end­points. Of pa­tients in the high dose group, 80% saw at least 75% skin clear­ance ver­sus 16% for place­bo. That num­ber was 70% in the low dose group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER